The funding will support the advancement of two programs into clinical trials and the development of a pipeline of novel pre-clinical programs for the treatment of depression and other neuropsychiatric disorders NEW YORK, Dec. 15, 2022 /PRNewswire/ — Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental…
Source